Table 1 Illustrative points system for the incremental-benefits variable
Dimensions | Points (weights) |
|---|---|
Lives saved, including ‘statistical’ lives (i.e. cure or reduced risk of death) |  |
 None (or not yet known) | 0 |
 Few: 1-50 lives saved | 0.091 |
 Some: 51-250 lives saved | 0.192 |
 Many: 251-500 lives saved | 0.268 |
 Very many: > 500 lives saved | 0.343 |
Life-prolongation benefits – in terms of increase in life expectancy and its quality-of-life, and number of patients affected |  |
 None/Very small (or not yet known) | 0 |
 Small benefits | 0.053 |
 Medium benefits | 0.152 |
 Large benefits | 0.244 |
Quality-of-life gains – in terms of baseline QoL, size of QoL gains and duration, and number of patients affected |  |
 None/Very small (or not yet known) | 0 |
 Small QoL gains | 0.051 |
 Medium QoL gains | 0.138 |
 Large QoL gains | 0.217 |
If this technology were not to be funded … |  |
 Many/most patients will be able to pay for it themselves (privately) | 0 |
 Many/most patients will get an alternative treatment (less effective) already funded by government | 0.055 |
 Many/most patients will not receive any treatment for condition | 0.108 |
Other important social or ethical benefits, e.g. targeted to children/minorities; reduces health gaps, etc | Â |
 None/Very small (or not yet known) | 0 |
 Yes | 0.087 |